148 related articles for article (PubMed ID: 16837630)
1. Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL.
van Galen JC; Muris JJ; Oudejans JJ; Vos W; Giroth CP; Ossenkoppele GJ; Otte AP; Raaphorst FM; Meijer CJ
J Clin Pathol; 2007 Feb; 60(2):167-72. PubMed ID: 16837630
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
[TBL] [Abstract][Full Text] [Related]
3. Implication of polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas.
Silva J; García JM; Peña C; García V; Domínguez G; Suárez D; Camacho FI; Espinosa R; Provencio M; España P; Bonilla F
Clin Cancer Res; 2006 Dec; 12(23):6929-36. PubMed ID: 17145810
[TBL] [Abstract][Full Text] [Related]
4. BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer.
Zhang XW; Sheng YP; Li Q; Qin W; Lu YW; Cheng YF; Liu BY; Zhang FC; Li J; Dimri GP; Guo WJ
Mol Cancer; 2010 Feb; 9():40. PubMed ID: 20170541
[TBL] [Abstract][Full Text] [Related]
5. Bmi1 promotes prostate tumorigenesis via inhibiting p16(INK4A) and p14(ARF) expression.
Fan C; He L; Kapoor A; Gillis A; Rybak AP; Cutz JC; Tang D
Biochim Biophys Acta; 2008 Nov; 1782(11):642-8. PubMed ID: 18817867
[TBL] [Abstract][Full Text] [Related]
6. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
7. Bmi1 promotes hepatic stem cell expansion and tumorigenicity in both Ink4a/Arf-dependent and -independent manners in mice.
Chiba T; Seki A; Aoki R; Ichikawa H; Negishi M; Miyagi S; Oguro H; Saraya A; Kamiya A; Nakauchi H; Yokosuka O; Iwama A
Hepatology; 2010 Sep; 52(3):1111-23. PubMed ID: 20648475
[TBL] [Abstract][Full Text] [Related]
8. Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas.
Paik JH; Jeon YK; Park SS; Kim YA; Kim JE; Huh J; Lee SS; Kim WH; Kim CW
Histopathology; 2005 Sep; 47(3):281-91. PubMed ID: 16115229
[TBL] [Abstract][Full Text] [Related]
9. Bmi1, stem cells, and senescence regulation.
Park IK; Morrison SJ; Clarke MF
J Clin Invest; 2004 Jan; 113(2):175-9. PubMed ID: 14722607
[TBL] [Abstract][Full Text] [Related]
10. Bmi1 functions as an oncogene independent of Ink4A/Arf repression in hepatic carcinogenesis.
Xu CR; Lee S; Ho C; Bommi P; Huang SA; Cheung ST; Dimri GP; Chen X
Mol Cancer Res; 2009 Dec; 7(12):1937-45. PubMed ID: 19934271
[TBL] [Abstract][Full Text] [Related]
11. p63 protein expression in high risk diffuse large B-cell lymphoma.
Hallack Neto AE; Siqueira SA; Dulley FL; Ruiz MA; Chamone DA; Pereira J
J Clin Pathol; 2009 Jan; 62(1):77-9. PubMed ID: 19103865
[TBL] [Abstract][Full Text] [Related]
12. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.
Hoeller S; Schneider A; Haralambieva E; Dirnhofer S; Tzankov A
Histopathology; 2010 Jul; 57(1):73-80. PubMed ID: 20579129
[TBL] [Abstract][Full Text] [Related]
13. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
van Galen JC; Muris JJ; Giroth CP; Vos W; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
Histopathology; 2008 Apr; 52(5):578-84. PubMed ID: 18312353
[TBL] [Abstract][Full Text] [Related]
14. p16Ink4a suppression of lung adenocarcinoma by Bmi-1 in the presence of p38 activation.
Lee MO; Lee HJ; Kim MA; Kim EK; Lee JH; Heo JH; Lee SH; Cho SH; Fornace AJ; Jeong HC; Cha HJ
J Thorac Oncol; 2011 Mar; 6(3):423-31. PubMed ID: 21164364
[TBL] [Abstract][Full Text] [Related]
15. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.
Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C
Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049
[TBL] [Abstract][Full Text] [Related]
16. High expression of p16INK4a and low expression of Bmi1 are associated with endothelial cellular senescence in the human cornea.
Wang Y; Zang X; Wang Y; Chen P
Mol Vis; 2012; 18():803-15. PubMed ID: 22509111
[TBL] [Abstract][Full Text] [Related]
17. Dysregulated expression of stem cell factor Bmi1 in precancerous lesions of the gastrointestinal tract.
Tateishi K; Ohta M; Kanai F; Guleng B; Tanaka Y; Asaoka Y; Tada M; Seto M; Jazag A; Lianjie L; Okamoto M; Isayama H; Tada M; Yoshida H; Kawabe T; Omata M
Clin Cancer Res; 2006 Dec; 12(23):6960-6. PubMed ID: 17145814
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of a two-gene expression index for subtype classification and prognosis in Diffuse Large B-Cell Lymphoma.
Xu Q; Tan C; Ni S; Wang Q; Wu F; Liu F; Ye X; Meng X; Sheng W; Du X
Sci Rep; 2015 May; 5():10006. PubMed ID: 25940947
[TBL] [Abstract][Full Text] [Related]
19. Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma.
Ochiai H; Takenobu H; Nakagawa A; Yamaguchi Y; Kimura M; Ohira M; Okimoto Y; Fujimura Y; Koseki H; Kohno Y; Nakagawara A; Kamijo T
Oncogene; 2010 May; 29(18):2681-90. PubMed ID: 20190806
[TBL] [Abstract][Full Text] [Related]
20. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.
Iqbal J; Neppalli VT; Wright G; Dave BJ; Horsman DE; Rosenwald A; Lynch J; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Campo E; Ott G; Müller-Hermelink HK; Delabie J; Jaffe ES; Grogan TM; Connors JM; Vose JM; Armitage JO; Staudt LM; Chan WC
J Clin Oncol; 2006 Feb; 24(6):961-8. PubMed ID: 16418494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
